Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model

Hans Layman, Marianne Sacasa, Ashley E. Murphy, Amy M. Murphy, Si M. Pham, Fotios M Andreopoulos

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Peripheral artery disease and critical limb ischemia have become prevalent health risks in the United States due to an increasing elderly population and the prevalence of obesity and diabetes mellitus. Although highly invasive endarterectomy is the most popular method for treatment, angiogenic therapies based on growth factor administration are quickly becoming a popular alternative. Enzymatic degradation of these factors in vivo may be avoided by their incorporation in a delivery vehicle where the growth factor's release rate can be controlled by altering the vehicle's properties (i.e. cross-linking density, material selection, biodegradation, etc.). Herein, we report on the immobilization and controlled release of human recombinant basic fibroblast growth factor (FGF-2) and human recombinant granulocyte colony-stimulating factor (G-CSF) from ionic, gelatin-based hydrogel scaffolds to re-establish perfusion and induce capillary outgrowth in a murine hindlimb ischemic model. In vitro studies showed that endothelial cell proliferation was highly depended on FGF-2, whereas G-CSF stimulated migration and formation of a tubular network. When FGF-2 and G-CSF were used in combination there was an 82% increase in endothelial branch point formation compared to control groups. Leg reperfusion was assessed with laser Doppler perfusion imaging, while capillary outgrowth in the ischemic leg was evaluated using CD31+ and α-SMA immunostaining. The co-delivery of G-CSF (1000 ng ml-1) and FGF-2 (1000 ng ml-1) from the gelatin hydrogels resulted in a 3-fold increase in the perfusion levels and a 2-fold increase in capillary density and positive α-SMA vessels compared to the empty vehicle group. In conclusion, the co-delivery of FGF-2 and G-CSF was superior to bolus administration or the delivery of either factor alone in promoting reperfusion and mature vessel formation.

Original languageEnglish
Pages (from-to)230-239
Number of pages10
JournalActa Biomaterialia
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

Hydrogels
Fibroblast Growth Factor 2
Granulocyte Colony-Stimulating Factor
Gelatin
Extremities
Health risks
Endothelial cells
Cell proliferation
Fibroblasts
Medical problems
Biodegradation
Intercellular Signaling Peptides and Proteins
Scaffolds
Reperfusion
Leg
Therapeutics
Perfusion
Hydrogel
Imaging techniques
Degradation

Keywords

  • Angiogenesis
  • Basic fibroblast growth factor
  • Controlled delivery
  • Hydrogels
  • Ischemia

ASJC Scopus subject areas

  • Biomaterials
  • Biomedical Engineering
  • Biotechnology
  • Biochemistry
  • Molecular Biology

Cite this

Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. / Layman, Hans; Sacasa, Marianne; Murphy, Ashley E.; Murphy, Amy M.; Pham, Si M.; Andreopoulos, Fotios M.

In: Acta Biomaterialia, Vol. 5, No. 1, 01.01.2009, p. 230-239.

Research output: Contribution to journalArticle

Layman, Hans ; Sacasa, Marianne ; Murphy, Ashley E. ; Murphy, Amy M. ; Pham, Si M. ; Andreopoulos, Fotios M. / Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. In: Acta Biomaterialia. 2009 ; Vol. 5, No. 1. pp. 230-239.
@article{1a00dc13bc5844d186b791f934654ac4,
title = "Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model",
abstract = "Peripheral artery disease and critical limb ischemia have become prevalent health risks in the United States due to an increasing elderly population and the prevalence of obesity and diabetes mellitus. Although highly invasive endarterectomy is the most popular method for treatment, angiogenic therapies based on growth factor administration are quickly becoming a popular alternative. Enzymatic degradation of these factors in vivo may be avoided by their incorporation in a delivery vehicle where the growth factor's release rate can be controlled by altering the vehicle's properties (i.e. cross-linking density, material selection, biodegradation, etc.). Herein, we report on the immobilization and controlled release of human recombinant basic fibroblast growth factor (FGF-2) and human recombinant granulocyte colony-stimulating factor (G-CSF) from ionic, gelatin-based hydrogel scaffolds to re-establish perfusion and induce capillary outgrowth in a murine hindlimb ischemic model. In vitro studies showed that endothelial cell proliferation was highly depended on FGF-2, whereas G-CSF stimulated migration and formation of a tubular network. When FGF-2 and G-CSF were used in combination there was an 82{\%} increase in endothelial branch point formation compared to control groups. Leg reperfusion was assessed with laser Doppler perfusion imaging, while capillary outgrowth in the ischemic leg was evaluated using CD31+ and α-SMA immunostaining. The co-delivery of G-CSF (1000 ng ml-1) and FGF-2 (1000 ng ml-1) from the gelatin hydrogels resulted in a 3-fold increase in the perfusion levels and a 2-fold increase in capillary density and positive α-SMA vessels compared to the empty vehicle group. In conclusion, the co-delivery of FGF-2 and G-CSF was superior to bolus administration or the delivery of either factor alone in promoting reperfusion and mature vessel formation.",
keywords = "Angiogenesis, Basic fibroblast growth factor, Controlled delivery, Hydrogels, Ischemia",
author = "Hans Layman and Marianne Sacasa and Murphy, {Ashley E.} and Murphy, {Amy M.} and Pham, {Si M.} and Andreopoulos, {Fotios M}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.actbio.2008.07.024",
language = "English",
volume = "5",
pages = "230--239",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model

AU - Layman, Hans

AU - Sacasa, Marianne

AU - Murphy, Ashley E.

AU - Murphy, Amy M.

AU - Pham, Si M.

AU - Andreopoulos, Fotios M

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Peripheral artery disease and critical limb ischemia have become prevalent health risks in the United States due to an increasing elderly population and the prevalence of obesity and diabetes mellitus. Although highly invasive endarterectomy is the most popular method for treatment, angiogenic therapies based on growth factor administration are quickly becoming a popular alternative. Enzymatic degradation of these factors in vivo may be avoided by their incorporation in a delivery vehicle where the growth factor's release rate can be controlled by altering the vehicle's properties (i.e. cross-linking density, material selection, biodegradation, etc.). Herein, we report on the immobilization and controlled release of human recombinant basic fibroblast growth factor (FGF-2) and human recombinant granulocyte colony-stimulating factor (G-CSF) from ionic, gelatin-based hydrogel scaffolds to re-establish perfusion and induce capillary outgrowth in a murine hindlimb ischemic model. In vitro studies showed that endothelial cell proliferation was highly depended on FGF-2, whereas G-CSF stimulated migration and formation of a tubular network. When FGF-2 and G-CSF were used in combination there was an 82% increase in endothelial branch point formation compared to control groups. Leg reperfusion was assessed with laser Doppler perfusion imaging, while capillary outgrowth in the ischemic leg was evaluated using CD31+ and α-SMA immunostaining. The co-delivery of G-CSF (1000 ng ml-1) and FGF-2 (1000 ng ml-1) from the gelatin hydrogels resulted in a 3-fold increase in the perfusion levels and a 2-fold increase in capillary density and positive α-SMA vessels compared to the empty vehicle group. In conclusion, the co-delivery of FGF-2 and G-CSF was superior to bolus administration or the delivery of either factor alone in promoting reperfusion and mature vessel formation.

AB - Peripheral artery disease and critical limb ischemia have become prevalent health risks in the United States due to an increasing elderly population and the prevalence of obesity and diabetes mellitus. Although highly invasive endarterectomy is the most popular method for treatment, angiogenic therapies based on growth factor administration are quickly becoming a popular alternative. Enzymatic degradation of these factors in vivo may be avoided by their incorporation in a delivery vehicle where the growth factor's release rate can be controlled by altering the vehicle's properties (i.e. cross-linking density, material selection, biodegradation, etc.). Herein, we report on the immobilization and controlled release of human recombinant basic fibroblast growth factor (FGF-2) and human recombinant granulocyte colony-stimulating factor (G-CSF) from ionic, gelatin-based hydrogel scaffolds to re-establish perfusion and induce capillary outgrowth in a murine hindlimb ischemic model. In vitro studies showed that endothelial cell proliferation was highly depended on FGF-2, whereas G-CSF stimulated migration and formation of a tubular network. When FGF-2 and G-CSF were used in combination there was an 82% increase in endothelial branch point formation compared to control groups. Leg reperfusion was assessed with laser Doppler perfusion imaging, while capillary outgrowth in the ischemic leg was evaluated using CD31+ and α-SMA immunostaining. The co-delivery of G-CSF (1000 ng ml-1) and FGF-2 (1000 ng ml-1) from the gelatin hydrogels resulted in a 3-fold increase in the perfusion levels and a 2-fold increase in capillary density and positive α-SMA vessels compared to the empty vehicle group. In conclusion, the co-delivery of FGF-2 and G-CSF was superior to bolus administration or the delivery of either factor alone in promoting reperfusion and mature vessel formation.

KW - Angiogenesis

KW - Basic fibroblast growth factor

KW - Controlled delivery

KW - Hydrogels

KW - Ischemia

UR - http://www.scopus.com/inward/record.url?scp=56349147736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349147736&partnerID=8YFLogxK

U2 - 10.1016/j.actbio.2008.07.024

DO - 10.1016/j.actbio.2008.07.024

M3 - Article

C2 - 18713669

AN - SCOPUS:56349147736

VL - 5

SP - 230

EP - 239

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 1

ER -